GlaxoSmithKline PLC (GSK): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

GlaxoSmithKline ( GSK) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.7%. By the end of trading, GlaxoSmithKline fell 52 cents (-1.1%) to $46.14 on average volume. Throughout the day, 2.4 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 1.9 million shares. The stock ranged in price between $46.12-$46.41 after having opened the day at $46.21 as compared to the previous trading day's close of $46.66. Other companies within the Drugs industry that declined today were: CytRx Corporation ( CYTR), down 11.7%, MEI Pharma ( MEIP), down 9.5%, Inovio Pharmaceuticals ( INO), down 8.7%, and Aoxing Pharmaceutical Company ( AXN), down 7.9%.
  • ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $116.74 billion and is part of the health care sector. The company has a P/E ratio of 13.9, below the average drugs industry P/E ratio of 14.3 and below the S&P 500 P/E ratio of 17.7. Shares are up 2.2% year to date as of the close of trading on Tuesday. Currently there are two analysts that rate GlaxoSmithKline a buy, no analysts rate it a sell, and seven rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, notable return on equity, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, Peregrine Pharmaceuticals ( PPHM), up 24.3%, Prana Biotechnology ( PRAN), up 18.9%, InterMune ( ITMN), up 16.3%, and Zalicus ( ZLCS), up 9.8%, were all gainers within the drugs industry with Alexion Pharmaceuticals ( ALXN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

These Stocks Pay You to Own Them

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment